TP53 mutation and integrin β4 overexpression co-occur in many aggressive malignancies, and lung squamous cell carcinoma has a higher TP53 mutation frequency; the overexpression of integrin β4 can also lead to venous infiltration and a reduction in overall survival in patients with non-small cell lung cancer [17]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.